- NIH acknowledges KEI/UACT request to use royalty-free or march-in rights on Xtandi
- Feasibility study on a TDR pooled fund for R&D to be released on 20 February 2016
- SAVE THE DATE - 26 January 2016: Implications of the TPP and RCEP on Universal Health Coverage
- Xtandi 2016 March-In Request
- Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes
- 51 members of Congress have asked the NIH to use March-In rights to rein in high drug prices
- WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual property
- FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
- KEI's December 19, 2015 submission to the US ITC regarding the TPP
- The UK's rebates on drug sales, and introducing the budget constraint into pricing models
Key WIPO committee on patents to discuss patents and health, exceptions and limitations to patent rights and opposition systemsSubmitted by thiru on 14. May 2012 - 3:35
The World Intellectual Property Organization (WIPO) will convene the 18th session of the WIPO Standing Committee on the Law of Patents (SCP) from 21 May 2012 to 25 May 2012 (during the same week as the 65th session of the World Health Assembly). The agenda of the SCP is reproduced below.
This was the 3,500 word statement of Senator Bernie Sanders during Senate HELP committee markup of the PDUFA legislation. The statement covers a lot of ground, and illustrates why consumer groups love Bernie Sanders, while making one wonder why other Senators have not been more supportive of the consumer protection issues that Sanders discusses. Here are some highlights:
- The proposal for a new extended monopoly for antibiotics and antifungal drugs is a "huge giveaway" that will lead to high prices and harm consumers.
Manon Ress obtained the following quotes for various antiretroviral drugs on May 9, 2012.
The products are described briefly in the following chart, which provides details on the recommended dose: http://www.aidsmeds.com/articles/DrugChart_10632.shtml
The FDA web page on Antiretroviral drugs used in the treatment of HIV infection: http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAID...
The prices were obtained from http://www.goodrx.com/. for pharmacies in or near Arlington, Virginia or Washington, DC.
Update: the hearing web page is here: http://www.help.senate.gov/hearings/hearing/?id=2d5dda75-5056-9502-5d1a-2a40d8a92d51
On May 15, 2012, the Primary Health and Aging Subcommittee of the Senate HELP Committee will hold hearings on S.1138, the Prize Fund for HIV/AIDS.
COMMITTEE ON HEALTH, EDUCATION, LABOR AND PENSIONS
Primary Health and Aging Subcommittee
The WHO's Consultative Expert Working Group (CEWG) on R&D proposal for a new WHO Convention on health R&D has been widely praised by public health groups (See http://www.keionline.org/node/1399). The CEWG proposal for a treaty has also, at least so far, avoided much criticism from the pharmaceutical industry, even though it strongly embraces the notion of delinkage of R&D costs from product prices, open innovation, and technology transfer and capacity building in developing countries.
The USTR's 2012 Special 301 list was published on April 30, 2012. Below are some comments about certain portions of the Special 301 Report that concern access to knowledge and access to medicines.
USTR cites the "TEAM" approach to access to medicines
The 2012 USTR Special 301 Report was published on April 30, 2012. The report details USTR's unilateral standards for the granting and enforcement for a diverse set of intellectual property rights, and singles out countries that USTR claims do not meet those standards. The Report places the offending countries into different categories, including those on the “Priority Watch List,” the “Watch List” and those to have a “Special 306” review. According to USTR:
Senate HELP Committee proposes evaluation of Innovation Inducement Prizes, as alternative to product monopoliesSubmitted by James Love on 25. April 2012 - 2:48
In the United States Senate, the Committee on Health, Education, Labor and Pensions (HELP) is trying to move forward a bill titled the "Food and Drug Administration Safety and Innovation Act." Among other things, the bill would "amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, establish user-fee programs for generic drugs and biosimilars," and address a number of other topics, such as extend the legal monopoly on antibiotic drugs by 5 years.
On Wednesday, April 25, 2012 at 10:00 AM, the Senate Health, Education, Labor and Pensions (HELP) Committee will have an executive session to do a markup of FDA bills.
On Thursday, 5 April 2012, the World Health Organization released the report of the Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) entitled "Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination".
5 April 2012: World Health Organization's Consultative Expert Working Group on R&D Financing releases its ReportSubmitted by thiru on 5. April 2012 - 6:49
On Thursday, 5 April 2012, the World Health Organization released the report of the Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination entitled "Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination". The 218 page report will take some time to fully assess.
The report can be found here: http://www.who.int/phi/CEWG_Report_5_April_2012.pdf
Senator Harkin (D-IA) sends letter to President Obama supporting a WIPO treaty for the visually impairedSubmitted by Krista Cox on 1. April 2012 - 18:42
On Friday, March 30, 2012, Senator Tom Harkin (D-IA), Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee sent a letter to President Obama supporting an international treaty for persons who are visually impaired or have other disabilities. The letter urges the Obama administration to achieve several goals in such a treaty, including robust minimum standards that do not diminish the rights provided for under U.S.
On March 12, 2012, Tedmund Wan posted a note on Joe Biden's appointment of Steve Ricchetti, exploring potential conflicts of interest with the clients in a lobbying firm that he ran. On March 29, 2012, KEI formally asked Ricchetti to recuse himself in matters concerning his former clients. The letter follows.
29 March 2012
Counselor to Vice President Joe Biden
The White House
In response to a Federal Register notice seeking comments on genetic diagnostic testing, KEI submitted comments detailing several proposals with respect to patents on diagnostic technologies and also included notes regarding our position in the American Molecular Pathology v. Myriad Genetics litigation. In addition to the questions listed in Federal Register notice, we recommended that the USPTO address two additional questions: